iStock-534890661.jpg

Our Pipeline

OUR PIPELINE

Dragonfly's novel cytokines and "TriNKET" NK cell engagers can both kill cancers and other disease targets directly, and improve the outcomes of other immunotherapy approaches like T-cell therapies.

Dragonfly’s pipeline is robust and continues to grow both internally and with BMS, Merck, and AbbVie

PRECLINICAL

IND FILING 

PHASE I

PHASE II

DF1001 HER2-Targeting TriNKET

DF9001 (Solid Tumor) TriNKET

DF7001 (Solid Tumor) TriNKET

DF6200 (Oncology) Cytokine

DF5300 (Immunology) TriNKET

Dragonfly 10+ Preclinical TriNKETs

DF6002 (BMS-licensed) IL-12 Cytokine

DF2001 (BMS-licensed) Heme TriNKET

DF3001 (BMS-licensed) Heme TriNKET

DF4001 (BMS-licensed) Heme TriNKET

DF5008 (BMS-licensed) Heme TriNKET

DF2200 (BMS-licensed) Heme TriNKET

DF8000 (Merck-licensed) TriNKET

DF8100 (Merck-licensed) TriNKET

DF4100 (AbbVie-licensed) TriNKET

Dragonfly 6+ Partnered TriNKETs